I. Bondarenko

发表

Abstract S1-6: Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (BC)

R. Finn, T. Pintér, J. Crown, 2012 .

378MO EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%

I. Lowy, V. Sriuranpong, P. Clingan, 2020, Annals of Oncology.

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

N. Reinmuth, N. Shire, Haiyi Jiang, 2019, Journal of Thoracic Oncology.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA61 Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the phase III CASPIAN study

N. Reinmuth, Yuh-Min Chen, L. Paz-Ares, 2021, Annals of Oncology.

Randomized multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and a prospective evaluation of the of the association between tumor hENT1 expression and clinical outcome with gemcitabine treatment.

V. Heinemann, C. Bassi, H. Wasan, 2013 .

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

H. Mann, M. Hochmair, L. Havel, 2022, ESMO open.

Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.

V. Heinemann, A. Dicker, C. Bassi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor–Positive Locally Advanced or Metastatic Breast Cancer

G. Acton, N. Ibrahim, J. Murray, 2011, Clinical Cancer Research.

FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer

M. Ellis, J. Robertson, A. Manikhas, 2016 .

PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC

A. Chella, H. Wakelee, C. Zhou, 2022, Journal of Thoracic Oncology.

80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study

A. Chella, H. Wakelee, C. Zhou, 2022, Annals of Oncology.

283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial

C. Barrios, J. O’Shaughnessy, M. Wongchenko, 2020 .

518O Overall survival results from ARIEL4: A phase III study assessing rucaparib vs chemotherapy in patients with advanced, relapsed ovarian carcinoma and a deleterious BRCA1/2 mutation

A. Oza, D. Cibula, K. Mclachlan, 2022, Annals of Oncology.

LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

I. Lowy, M. Gumus, M. Schenker, 2022, Annals of Oncology.